CALRETICULIN: A NOVEL ANTITHROMBOTIC AGENT

 

Introduction:   The subject invention provides a pharmaceutical composition, which comprises an amount of calreticulin effective for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, and a pharmaceutically effective carrier.

The subject invention provides a method for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, which method comprises administering calreticulin to the subject in an amount effective for blocking or preventing thrombosis.

The subject invention provides a pharmaceutical composition that comprises calreticulin in combination with another antithrombotic agent, in an amount and proportion effective for enhancing the action of the other antithrombotic agent, to prevent clotting or to dissolve clots which have already formed.

The subject invention provides a method for enhancing the action of another antithrombotic agent that prevents clotting or dissolves clots that have already formed, comprising administering to a subject calreticulin in combination with the other antithrombotic agent in an amount and proportion for enhancing the action of the other antithrombotic agent, to prevent clotting or to dissolve clots that have already formed.

 

NON-CONFIDENTIAL TECHNOLOGY DESCRIPTION

The preceding is intended to be a non-confidential summary of a novel technology created at the University of Texas Health Science center at Houston (UTHSCH), for which the University has obtained patent protection. 

UTHSCH Ref. No. 1993-0003

Inventors: Dr. Claude Benedict

Patent Status: United State Patent No. 5,426,097

License Available: world-wide; exclusive or non-exclusive

 

To obtain further information about this technology, please contact:
Office of Technology Management, 7000 Fannin, Suite 720, Houston, TX 77030
Phone: (713) 500-3369  Fax: (713) 500-0331
Email: uthsch-otm@uth.tmc.edu